The alzheimer's diagnostics and therapeutics market is projected to grow from USD 7.8 billion in 2025 to USD 17.4 billion by 2035, at a CAGR of 8.4%. Therapeutics will dominate with a 54.7% market share, while institutional sales will lead the distribution channel segment with a 46.3% share.